Literature DB >> 24135576

Vaccination coverage levels among children enrolled in the Vaccine Safety Datalink.

Natalie L McCarthy1, Stephanie Irving, James G Donahue, Eric Weintraub, Julianne Gee, Edward Belongia, James Baggs.   

Abstract

INTRODUCTION: The Vaccine Safety Datalink (VSD) is a collaborative project whose infrastructure provides comprehensive medical and immunization histories for more than 9 million adults and children annually, a predominantly insured population. This study provides the coverage rates of recommended vaccines among children 19-35 months in the VSD from 2005 through 2010. We examine the consistency in vaccine coverage levels, detect possible trends, and evaluate any effect of vaccine shortages on coverage in the VSD.
METHODS: We included data from all 10 VSD sites, and examined each year independently. Coverage rates were defined as the percentage of children in the VSD aged 19, 24, or 35 months in a given study year who had received the specified Advisory Committee on Immunization Practices (ACIP) recommended vaccine(s).
RESULTS: We assessed coverage on 658,154 children. The overall coverage rate for children receiving all of the specified ACIP recommended vaccines was 73%, 80%, and 78% at ages 19, 24, and 35 months respectively. The range of coverage across all ages and years was 95-97% for polio vaccine, 91-97%, for MMR vaccine, 94-97% for HepB vaccine, 81-95% for DTaP vaccine, 90-95% for varicella vaccine, 66-91% for PCV, and 93-98% for Hib vaccine. Coverage rates of 4 or more doses of PCV were relatively low in 2005 possibly due to a vaccine shortage, and increased sharply in 2007. Hib vaccine coverage was relatively stable among all ages until 2009 when rates declined among children aged 19 and 24 months also during a vaccine shortage.
CONCLUSIONS: Vaccine coverage in the VSD is high, but there is a decline from 2005 to 2010. The results of this study provide benchmark data for future studies, and describe how vaccine supply shortages and resulting changes in ACIP recommendations may have affected vaccine coverage rates in the VSD. Published by Elsevier Ltd.

Entities:  

Keywords:  Vaccine; Vaccine Safety Datalink; Vaccine coverage

Mesh:

Year:  2013        PMID: 24135576     DOI: 10.1016/j.vaccine.2013.10.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Drug shortages and implications for pediatric patients.

Authors:  Lindsay Butterfield; Jared Cash; Kathy Pham
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

2.  Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population.

Authors:  Lakshmi Sukumaran; Natalie L McCarthy; Rongxia Li; Eric S Weintraub; Steven J Jacobsen; Simon J Hambidge; Lisa A Jackson; Allison L Naleway; Berwick Chan; Biwen Tao; Julianne Gee
Journal:  Vaccine       Date:  2015-07-23       Impact factor: 3.641

3.  Vaccination timeliness among newborns and infants in Ethiopia.

Authors:  Matthew L Boulton; Bradley F Carlson; Abram L Wagner; Julia M Porth; Berhanu Gebremeskel; Yemesrach Abeje
Journal:  PLoS One       Date:  2019-02-19       Impact factor: 3.240

4.  Vaccination timeliness and delay in low- and middle-income countries: a systematic review of the literature, 2007-2017.

Authors:  Nina B Masters; Abram L Wagner; Matthew L Boulton
Journal:  Hum Vaccin Immunother       Date:  2019-06-12       Impact factor: 3.452

5.  Vaccine coverage, timeliness and delay estimated from regional and national cross-sectional surveys in Ethiopia, 2016.

Authors:  Abram Luther Wagner; Yemesrach Abeje Tefera; Brenda Wilson Gillespie; Bradley Frederick Carlson; Matthew Lester Boulton
Journal:  Pan Afr Med J       Date:  2021-07-19

6.  Temporal Trends in Undervaccination: A Population-Based Cohort Study.

Authors:  Matthew F Daley; Liza M Reifler; Jo Ann Shoup; Komal J Narwaney; Elyse O Kharbanda; Holly C Groom; Michael L Jackson; Steven J Jacobsen; Huong Q McLean; Nicola P Klein; Joshua T B Williams; Eric S Weintraub; Michael M McNeil; Jason M Glanz
Journal:  Am J Prev Med       Date:  2021-04-30       Impact factor: 5.043

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.